Pfizer Files for FTZ Production Authority in Michigan

FTZ News: Pfizer has submitted a notification of proposed production activity to the Foreign-Trade Zones Board for its facilities in Kalamazoo and Portage, Michigan, located within Subzone 43E. The company seeks authority to produce phthalimido lactol, a pharmaceutical intermediate, under FTZ procedures. The foreign-status input identified in the filing is 3-phthalimidopropionaldehyde. Public comments on the notification are due by August 31, 2026.

Under FTZ rules, any authorized production activity is limited to the specific foreign-status materials and finished products described in the notification. The filing notes that the input material may be subject to duties under Section 232 of the Trade Expansion Act or Section 301 of the Trade Act of 1974, depending on country of origin. In such cases, the merchandise must be admitted to the zone in privileged foreign status, locking in the duty rate at the time of admission.

Pharmaceutical intermediates occupy a strategically sensitive segment of the drug-manufacturing supply chain. Many active pharmaceutical ingredients and their precursors are still sourced internationally. When those materials face additional tariffs, the ability to admit them into an FTZ and defer duty payment until the finished product enters U.S. commerce can materially affect production economics. If the intermediate is later exported, duties may be avoided entirely.

Pfizer’s Michigan sites form part of a long-established pharmaceutical manufacturing cluster. Subzone 43E already provides a customs framework for certain operations at these locations. The new notification seeks to expand the scope of authorized activity to include this specific intermediate. The Board will review whether the proposed production meets the criteria set out in the FTZ regulations, including the requirement that the activity not be detrimental to the public interest.

The timing of the filing is notable. Pharmaceutical companies have faced elevated uncertainty around tariff exposure on chemical inputs in recent years. Section 301 and Section 232 actions have layered additional duties on a range of industrial and chemical products. FTZ procedures offer one of the few remaining tools that allow manufacturers to manage that exposure while continuing to produce in the United States. By locking the duty rate at admission and deferring payment, companies gain both cash-flow advantages and greater predictability.

The privileged-foreign-status requirement adds a layer of complexity. Once merchandise is admitted in that status, the duty rate is fixed even if rates later change. Companies must therefore make a calculated decision about when and how to bring materials into the zone. Inventory control systems must be robust enough to track status and support accurate duty calculation upon entry into the U.S. market.

If the Board ultimately authorizes the activity, Pfizer will be able to conduct the specified production under zone procedures, subject to standard FTZ record-keeping and reporting obligations. The authorization would remain narrowly tailored; it would not open the door to unrestricted chemical manufacturing. That narrowness is intentional. The FTZ program is designed to facilitate specific, identifiable activities rather than to create open-ended duty-free manufacturing zones.

For the broader pharmaceutical sector, the filing illustrates a continuing pattern: large manufacturers are testing the boundaries of FTZ utility in an era of higher and more variable tariffs. Whether the Board approves the request will depend on the details of the application and any public comments received. In the meantime, the notification itself signals that even major pharmaceutical companies continue to see practical value in the FTZ mechanism for managing the cost of internationally sourced intermediates./.